id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2003-E-0067-0005,FDA,FDA-2003-E-0067,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-06-28T04:00:00Z,2004,6,,,2025-10-23T19:37:41Z,,0,0,0900006480481d4f
FDA-2003-E-0067-0004,FDA,FDA-2003-E-0067,Determination of Regulatory Review Period for Purposes of Patent Extension; ELOXATIN,Notice,General Notice,2003-12-02T05:00:00Z,2003,12,2003-12-02T05:00:00Z,,2025-10-23T19:35:22Z,03-29928,0,0,0900006480481d4d
FDA-2003-E-0067-0003,FDA,FDA-2003-E-0067,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-12T05:00:00Z,2003,11,,,2025-10-23T19:28:37Z,,0,0,0900006480481d2d
FDA-2003-E-0067-0002,FDA,FDA-2003-E-0067,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2003-10-06T04:00:00Z,2003,10,,,2025-10-23T19:24:59Z,,0,0,0900006480481d19
FDA-2003-E-0067-0001,FDA,FDA-2003-E-0067,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-07-29T04:00:00Z,2003,7,,,2025-10-23T19:21:53Z,,0,0,0900006480481cce